Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies-Reference-Cited by-同舟云学术

Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies

Published:2024-03-02 Issue:6 Volume:103 Page:2123-2131
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Reimann Patrick,Petzer Verena,Mündlein Axel,Hartmann Bernd,Severgnini Luciano,Winkler Alex,Lang Theresia,Huynh Minh,Gasser Klaus,Rüger Julia,Atzl Michele,Mink Sylvia,Fraunberger Peter,Schmidt Stefan,Steiner Normann,Griesmacher Andrea,Gunsilius Eberhard,Nachbaur David,Willenbacher Wolfgang,Wolf Dominik,Winder Thomas,Benda Magdalena Anna

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05671-6.pdf

Reference32 articles.

1. WHO. WHO Coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int/. Accessed 13.09.2023

2. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B et al (2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136(25):2881–2892

3. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A et al (2020) Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov 10(7):935–941

4. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G et al (2020) Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med 8(9):853–862

5. Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A et al (2021) Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. Br J Haematol. 195(4):523–531

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cilgavimab/tixagevimab;Reactions Weekly;2024-08-24